Literature DB >> 17350901

Development and validation of a liquid chromatography-tandem mass spectrometric method for the determination of the major metabolites of duloxetine in human plasma.

Darlene K Satonin1, Julie D McCulloch, Fengjiun Kuo, Mary Pat Knadler.   

Abstract

A sensitive bioanalytical method for the measurement of two major circulating metabolites of duloxetine [4-hydroxy duloxetine glucuronide (LY550408) and 5-hydroxy-6-methoxy duloxetine sulfate (LY581920)] in plasma is reported. This method produced acceptable precision and accuracy over the validation range of 1-1000 ng/mL. Several issues had to be addressed in order to develop an LC/MS/MS assay for these metabolites. First, 4-hydroxy duloxetine glucuronide required chromatographic resolution from the 5-, and 6-hydroxy duloxetine glucuronide isomers. Second, the glucuronide conjugate is readily ionized under positive ESI conditions, while the sulfate conjugate required negative ESI conditions to obtain adequate sensitivity. Finally, the chromatographic conditions needed to separate the glucuronide isomers were not suitable for the analysis of the sulfate conjugate. The present method addressed these challenges, and was successfully applied to multiple human pharmacokinetic studies in which subjects received oral doses of duloxetine hydrochloride.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17350901     DOI: 10.1016/j.jchromb.2007.02.025

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

1.  Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.

Authors:  Evelyn D Lobo; Michael Heathman; Han-Yi Kuan; Shobha Reddy; Lisa O'Brien; Celedon Gonzales; Michael Skinner; Mary Pat Knadler
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

2.  Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation.

Authors:  Evelyn D Lobo; Tonya Quinlan; Lisa O'Brien; Mary Pat Knadler; Michael Heathman
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

3.  In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.

Authors:  Evelyn D Lobo; Richard F Bergstrom; Shobha Reddy; Tonya Quinlan; Jill Chappell; Quan Hong; Barbara Ring; Mary Pat Knadler
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

4.  Disposable screen-printed sensors for determination of duloxetine hydrochloride.

Authors:  Nawal A Alarfaj; Reda A Ammar; Maha F El-Tohamy
Journal:  Chem Cent J       Date:  2012-01-21       Impact factor: 4.215

5.  Bioanalysis in drug discovery and development.

Authors:  Saurabh Pandey; Preeti Pandey; Gaurav Tiwari; Ruchi Tiwari
Journal:  Pharm Methods       Date:  2010-10

6.  S100B suppression alters polarization of infiltrating myeloid-derived cells in gliomas and inhibits tumor growth.

Authors:  Hang Gao; Ian Y Zhang; Leying Zhang; Yanyan Song; Shunan Liu; Hui Ren; Huili Liu; Hui Zhou; Yanping Su; Yihang Yang; Behnam Badie
Journal:  Cancer Lett       Date:  2018-08-02       Impact factor: 8.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.